Co-Diagnostics, Inc. Stock News

SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting.

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person press conference and liv...

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a...

Localized cloud environment is designed to support ongoing clinical studies and establish the digital foundation for future data commercialization strategies SALT LAKE CITY, Sept. 3, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announc...

Shipments of laboratory equipment and other mosquito abatement materials to overseas USAF base represent first international expansion of Vector Smart product line SALT LAKE CITY, Sept. 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today a...

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Co...